{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:19:26Z","timestamp":1787735966285,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01825-z","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:39:19Z","timestamp":1787733559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9633-7999","authenticated-orcid":false,"given":"Naga Praneeth","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagapavani","family":"Kandagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"15","key":"1825_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jama.2026.1114","volume":"335","author":"S Shen","year":"2026","unstructured":"Shen S, Brown KA, Green AK, Iyengar NM. Obesity and Cancer: A Translational Science Review. JAMA. 2026;335(15):1341\u201350. https:\/\/doi.org\/10.1001\/jama.2026.1114.","journal-title":"JAMA"},{"issue":"2","key":"1825_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3322\/caac.21499","volume":"69","author":"H Sung","year":"2019","unstructured":"Sung H, Siegel RL, Torre LA, et al. Global Patterns in Excess Body Weight and the Associated Cancer Burden. CA Cancer J Clin. 2019;69(2):88\u2013112. https:\/\/doi.org\/10.3322\/caac.21499.","journal-title":"CA Cancer J Clin"},{"key":"1825_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2025.07.007","author":"DA Lamabadusuriya","year":"2025","unstructured":"Lamabadusuriya DA, Jayasena H, Bopitiya AK, De Silva AD, Mmpt J. Obesity-Driven Inflammation and Cancer Risk: A Comprehensive Review. Semin Cancer Biol. 2025. https:\/\/doi.org\/10.1016\/j.semcancer.2025.07.007.","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"1825_CR4","doi-asserted-by":"publisher","first-page":"e194743","DOI":"10.1172\/JCI194743","volume":"135","author":"E Valencia-Rincon","year":"2025","unstructured":"Valencia-Rincon E, Rai R, Chandra V, Wellberg EA. GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. J Clin Invest. 2025;135(21):e194743. https:\/\/doi.org\/10.1172\/JCI194743.","journal-title":"J Clin Invest"},{"issue":"7","key":"1825_CR5","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1825_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cam4.4434","volume":"11","author":"SG Dashti","year":"2022","unstructured":"Dashti SG, Simpson JA, Viallon V, et al. Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of mediating effects. Cancer Med. 2022;11(4):1145\u201359. https:\/\/doi.org\/10.1002\/cam4.4434.","journal-title":"Cancer Med"},{"issue":"6","key":"1825_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 2024;36(6):1302\u201319.","journal-title":"Cell Metab"},{"key":"1825_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178290","author":"K Wawrzak-Pienkowska","year":"2025","unstructured":"Wawrzak-Pienkowska K, Pienkowski T, Golonko A, et al. Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients. Eur J Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178290.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"1825_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/dom.12291","volume":"16","author":"H Zhao","year":"2014","unstructured":"Zhao H, Wang L, Wei R, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway. Diabetes Obes Metab. 2014;16(9):850\u201360. https:\/\/doi.org\/10.1111\/dom.12291.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1825_CR10","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"C Iwaya","year":"2017","unstructured":"Iwaya C, Nomiyama T, Komatsu S, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kappaB activation. Endocrinology. 2017;158(12):4218\u201332. https:\/\/doi.org\/10.1210\/en.2017-00461.","journal-title":"Endocrinology"},{"issue":"6","key":"1825_CR11","doi-asserted-by":"publisher","first-page":"e70913","DOI":"10.1002\/jbt.70913","volume":"40","author":"B Refaat","year":"2026","unstructured":"Refaat B, Elzubier ME, Aslam A, Idris S, Farrash WF. The GLP-1 receptor agonist liraglutide promotes anticancer activities in MCF7 breast and PC-3 prostate cancer cells by modulating glycolysis, oxidative stress and adipokines. J Biochem Mol Toxicol. 2026;40(6):e70913. https:\/\/doi.org\/10.1002\/jbt.70913.","journal-title":"J Biochem Mol Toxicol"},{"issue":"3","key":"1825_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/1078-0432.CCR-25-2819","volume":"32","author":"V Podder","year":"2026","unstructured":"Podder V, Coleman RL, Hagemann AR, Singhania P, Powell MA, Herzog TJ, Slomovitz BM. Repositioning GLP-1 receptor agonists in endometrial cancer: molecular rationale, preclinical insights, and translational opportunities. Clin Cancer Res. 2026;32(3):447\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2819.","journal-title":"Clin Cancer Res"},{"key":"1825_CR13","doi-asserted-by":"publisher","DOI":"10.1039\/d5fo03273c","author":"Y Luo","year":"2025","unstructured":"Luo Y, Xu H, Zhao Y, Yang B, Zhang Y. GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies. Food Funct. 2025. https:\/\/doi.org\/10.1039\/d5fo03273c.","journal-title":"Food Funct"},{"issue":"10","key":"1825_CR14","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/14796694.2026.2654735","volume":"22","author":"C Frey","year":"2026","unstructured":"Frey C. GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence. Future Oncol. 2026;22(10):1221\u201331. https:\/\/doi.org\/10.1080\/14796694.2026.2654735.","journal-title":"Future Oncol"},{"issue":"19","key":"1825_CR15","doi-asserted-by":"publisher","first-page":"e195484","DOI":"10.1172\/jci.insight.195484","volume":"10","author":"AG Pachimatla","year":"2025","unstructured":"Pachimatla AG, Fitzgerald B, Ogidigo J, et al. Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control. JCI Insight. 2025;10(19):e195484. https:\/\/doi.org\/10.1172\/jci.insight.195484.","journal-title":"JCI Insight"},{"issue":"10","key":"1825_CR16","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/jnci\/djaf163","volume":"117","author":"X Mao","year":"2025","unstructured":"Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. J Natl Cancer Inst. 2025;117(10):2053\u201363. https:\/\/doi.org\/10.1093\/jnci\/djaf163.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1825_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","volume":"11","author":"H Dai","year":"2025","unstructured":"Dai H, Li Y, Lee YA, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11(10):1186\u201393. https:\/\/doi.org\/10.1001\/jamaoncol.2025.2681.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1825_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers17010078","volume":"17","author":"S Levy","year":"2025","unstructured":"Levy S, Attia A, Elshazli RM, et al. Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients. Cancers (Basel). 2025;17(1):78. https:\/\/doi.org\/10.3390\/cancers17010078.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1825_CR19","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1111\/dom.16445","volume":"27","author":"LA Mavromatis","year":"2025","unstructured":"Mavromatis LA, Surapaneni A, Mehta S, et al. Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: a target-trial emulation study. Diabetes Obes Metab. 2025;27(8):4571\u20135. https:\/\/doi.org\/10.1111\/dom.16445.","journal-title":"Diabetes Obes Metab"},{"key":"1825_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24366","author":"Y Lu","year":"2025","unstructured":"Lu Y, Dai H, Tang H, et al. Association of glucagon-like peptide-1 receptor agonists with cancer risk in older adults with type 2 diabetes. Obes (Silver Spring). 2025. https:\/\/doi.org\/10.1002\/oby.24366.","journal-title":"Obes (Silver Spring)"},{"issue":"2","key":"1825_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/dom.70267","volume":"28","author":"AE Henney","year":"2026","unstructured":"Henney AE, Heague M, Riley DR, Hydes TJ, Anson M, Alam U, Cuthbertson DJ. Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes. Diabetes Obes Metab. 2026;28(2):946\u201359. https:\/\/doi.org\/10.1111\/dom.70267.","journal-title":"Diabetes Obes Metab"},{"key":"1825_CR22","doi-asserted-by":"publisher","unstructured":"Hsu AHC, Ramirez PT, Chang YH et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Ann Oncol 2026 Jun 7:S0923-7534(26)00157\u20132. https:\/\/doi.org\/10.1016\/j.annonc.2026.04.013","DOI":"10.1016\/j.annonc.2026.04.013"},{"issue":"2","key":"1825_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","volume":"179","author":"A Ko","year":"2026","unstructured":"Ko A, Chang YC, Bahar F, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med. 2026;179(2):216\u201329. https:\/\/doi.org\/10.7326\/ANNALS-25-02237.","journal-title":"Ann Intern Med"},{"key":"1825_CR24","doi-asserted-by":"publisher","first-page":"113158","DOI":"10.1016\/j.diabres.2026.113158","volume":"234","author":"YA Ateiwi","year":"2026","unstructured":"Ateiwi YA, Mahmood R, Wong HJ, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;234:113158. https:\/\/doi.org\/10.1016\/j.diabres.2026.113158.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1825_CR25","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1111\/dom.16489","volume":"27","author":"GA Silverii","year":"2025","unstructured":"Silverii GA, Marinelli C, Bettarini C, Del Vescovo GG, Monami M, Mannucci E. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025;27(8):4454\u201368. https:\/\/doi.org\/10.1111\/dom.16489.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1825_CR26","doi-asserted-by":"publisher","first-page":"e2080","DOI":"10.1210\/clinem\/dgae722","volume":"110","author":"CA Kelly","year":"2025","unstructured":"Kelly CA, Sipos JA. Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists. J Clin Endocrinol Metab. 2025;110(6):e2080\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgae722.","journal-title":"J Clin Endocrinol Metab"},{"key":"1825_CR27","unstructured":"NovoNordisk. Ozempic (semaglutide) injection, solution \/ tablets: U.S. prescribing information. Silver Spring, MD: US Food and Drug Administration; Updated January 30, 2026. Accessed August 24. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/213051Orig1s030lbl.pdf"},{"key":"1825_CR28","doi-asserted-by":"publisher","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","volume":"385","author":"B Pasternak","year":"2024","unstructured":"Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225. https:\/\/doi.org\/10.1136\/bmj-2023-078225.","journal-title":"BMJ"},{"issue":"2","key":"1825_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, Penichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390. https:\/\/doi.org\/10.2337\/dc22-1148.","journal-title":"Diabetes Care"},{"issue":"8","key":"1825_CR30","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1111\/dom.16504","volume":"27","author":"L Duchemin","year":"2025","unstructured":"Duchemin L, Morice A, Morice PM, et al. Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: a systematic review with meta-analysis of harms of randomized controlled trials. Diabetes Obes Metab. 2025;27(8):4607\u201310. https:\/\/doi.org\/10.1111\/dom.16504.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1825_CR31","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1210\/clinem\/dgaf703","volume":"111","author":"A Mahadevan","year":"2026","unstructured":"Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. J Clin Endocrinol Metab. 2026;111(6):1604\u201312. https:\/\/doi.org\/10.1210\/clinem\/dgaf703.","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 16","key":"1825_CR32","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1200\/JCO.2026.44.16_suppl.3143","volume":"44","author":"M Orland","year":"2026","unstructured":"Orland M, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol. 2026;44(suppl 16):3143. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.3143.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1825_CR33","doi-asserted-by":"publisher","first-page":"e2612133","DOI":"10.1001\/jamanetworkopen.2026.12133","volume":"9","author":"KL Tatum","year":"2026","unstructured":"Tatum KL, Dahman B, Stevenson A, et al. Survival and recurrence with GLP-1 receptor agonists in breast cancer. JAMA Netw Open. 2026;9(5):e2612133. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12133.","journal-title":"JAMA Netw Open"},{"key":"1825_CR34","unstructured":"National Library of Medicine (US). Tirzepatide for weight loss intervention in early-stage HR-positive\/HER2-negative breast cancer (FITWISE). ClinicalTrials.gov identifier: NCT06518837. Accessed August 24, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06518837"},{"key":"1825_CR35","unstructured":"ClinicalTrials.gov. Tirzepatide weight loss for MRD-positive early breast cancer (TRIM-EBC). NCT06517212."},{"issue":"2","key":"1825_CR36","doi-asserted-by":"publisher","first-page":"e2558205","DOI":"10.1001\/jamanetworkopen.2025.58205","volume":"9","author":"TT Yen","year":"2026","unstructured":"Yen TT, Hsieh TYJ, Lee GY, Toy EP, Wei JCC, Tanner EJ. GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases. JAMA Netw Open. 2026;9(2):e2558205. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.58205","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1825_CR37","doi-asserted-by":"publisher","first-page":"znag029","DOI":"10.1093\/bjs\/znag029","volume":"113","author":"HC Temperley","year":"2026","unstructured":"Temperley HC, Coalter M, Creavin B, et al. Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer. Br J Surg. 2026;113(4):znag029. https:\/\/doi.org\/10.1093\/bjs\/znag029.","journal-title":"Br J Surg"},{"issue":"3","key":"1825_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/dom.70394","volume":"28","author":"A Tentolouris","year":"2026","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I. If treating obesity with GLP-1-based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials. Diabetes Obes Metab. 2026;28(3):1599\u2013602. https:\/\/doi.org\/10.1111\/dom.70394.","journal-title":"Diabetes Obes Metab"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01825-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:39:21Z","timestamp":1787733561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01825-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01825-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}